AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
Study NCT02685397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
Study NCT02685397 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
Study NCT04023942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight maintenance intervention
Description: Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
Study NCT01461525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominoperineal resection
Description: After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
Study NCT01461525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphincter preservation surgery
Description: After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
Study NCT02300246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin
Description: Alveolar socket preservation with Platelet-Rich Plasma
Study NCT01319890 — intervention group
Intervention type: PROCEDURE
Intervention: Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)
Description: Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
Study NCT03787264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
Study NCT03787264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v.
Study NCT03787264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o.
Study NCT03787264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o.
Study NCT00459628 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Radiation treatment delivered by conventional linear accelerator using matching fields
Study NCT00459628 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
Study NCT02898883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Resilience after Childhood Emergencies (BRACE)
Description: See arm/group description for details regarding this intervention
Study NCT01015898 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
Study NCT01203098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 15mg
Description: DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
Study NCT01203098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b 30mg
Description: DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
Study NCT01203098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium 20 mg (=2000IU)
Description: Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
Study NCT01417442 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BRAF V600E POSITIVITY
Description: BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
Study NCT02211040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Plan
Description: The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans.
Study NCT00603616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching oral placebo pills to be taken twice daily for a total of 8 weeks
Study NCT00603616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
Study NCT03095612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor once weekly oral or twice weekly oral
Study NCT03095612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel once every 3 weeks (75 mg/m2 IV)
Study NCT04102787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac educational program
Description: Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management.
Study NCT02984111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT02984111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erythropoietin
Study NCT04351594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biofreeze 4 % Topical Gel
Description: Biofreeze gel with active manufactured ingredient (Menthol 4%)
Study NCT04351594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Biofreeze placebo gel
Description: Biofreeze gel with no active manufactured to have the same look, feel and odour as Biofreeze topical gel.
Study NCT01902199 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TRAA intervention
Description: The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
Study NCT04355650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool
Description: Adults (aged 18-64 years) who meet DSM-5 diagnostic criteria for non-psychotic unipolar major depressive disorder (MDD) and meet study eligibility criteria will receive 8 weeks of open-label treatment with an SSRI or SNRI antidepressant. Depressive symptoms will be assessed using the subject- and clinician-rated versions of the 16-items QIDS scale (QIDS-SR and QIDS-CR) and the 17-item HAMD at baseline, week 2 (via telephone), week 4, and week 8; with an additional phone contact at week 24. The QIDS scale scores at 2- and 4-weeks will be entered into the AHI-based clinical decision support tool, and the outcome predicted by the tool (e.g., the predicted eventual treatment outcome at 8 weeks) will be recorded. Clinicians and patients will be blinded to the clinical decision support tool prediction of outcome provided at the 2- and 4 weeks.
Study NCT01902199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TRAA intervention
Description: The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
Study NCT03266536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Western diet
Description: Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with \< 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
Study NCT01221792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day).
Study NCT01221792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non active comparator
Study NCT02218749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initially triaged to physiotherapist
Study NCT02218749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initially triaged to physician
Study NCT02334358 — intervention group
Intervention type: DEVICE
Intervention: YVOIRE Classic s
Study NCT02178735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior vaginal tailored mesh surgery
Description: Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
Study NCT02178735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior vaginal tailored mesh surgery
Description: Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
Study NCT02978664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water exchange
Description: Water will infused and removed during insertion phase of colonoscopy
Study NCT04278508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine if different serum P levels on FET day are associated with different clinical pregnancy rates (CPR)
Study NCT02581982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02581982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02581982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00141557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esterified estrogens 1.25mg and methyltestosterone 2.5mg
Description: ESTRATEST® administered orally QD
Study NCT00141557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esterified estrogens 1.25 mg
Description: Esterified estrogens 1.25 mg administered orally QD
Study NCT04372082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care (SOC)
Description: SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
Study NCT01654939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
Study NCT03902795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microperimetry
Description: Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
Study NCT03902795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: M-charts
Description: The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
Study NCT05230576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning training cohort
Description: train the deep learning model
Study NCT05230576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning validation cohort
Description: evaluate the model
Study NCT05000307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Analysing blood samples for the presence of antibody against SARS-CoV2. When impossible to collect sufficient B-cells for further typing, leucapheresis will be performed if the patient agrees.
Study NCT02568722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard RRT initiation
Description: In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization.
Study NCT02568722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Description: A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
Study NCT04285697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infection prevention bundle
Description: The infection prevention bundle (IPB) implemented items:~Preoperative counseling and questionnaire: patient counseling and preparation instructions, screening questions for signs of infection, and presence of open or nonhealing wounds.~Nasal methicillin-resistant and methicillin-sensitive Staphylococcus aureus decolonization: preoperative 24 hours ago twice-daily application of 2% mupirocin ointment to bilateral nares with final application on the morning of surgery.~Body decolonization: Cleansing with 4% chlorhexidine gluconate shower the evening before surgery and the morning of surgery.~Preoperative weight-based antibiotics within 60 minutes of incision~Strict draping and surgical techniques the standardization Irrigation of the surgical site with warm Isotonic NaCl solution before skin closure Postoperative wound care education to patient and family
Study NCT04390399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride
Study NCT04390399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: PD-L1 t-haNK suspension for infusion
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 2', 2'-difluoro 2'deoxycytidine, dFdC
Study NCT04372082 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen...) during the whole study duration
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Study NCT04390399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT04390399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy
Study NCT04390399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan liposome
Description: Irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano\[3',4':6,7\]-indolizino\[1,2-b\]quinolin-9-yl-\[1,4'bipiperidine\]-1'-carboxylate, monohydrochloride, trihydrate
Study NCT04372082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg x 3 per day during 10 days in addition to SOC
Study NCT04372082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association of diltiazem and niclosamide
Description: niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
Study NCT06357975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06357975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06357975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT06357975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT03444324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BT524
Description: BT524 was administered intravenously at a patient specific dosage depending on the type of surgery, the extent of bleeding and the subject's clinical condition.
Study NCT03444324 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FFP/Cryo
Description: FFP/Cryo was administered intravenously; dosage according to local standards in mL per kg body weight.
Study NCT02977078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active feedback on monitored inhaler use
Description: Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback